Tag - Corbus Pharmaceuticals

Corbus Pharma (CRBP) Receives EC Orphan Designation for Resunab as CF Treatment

Ziad2022-11-25T14:06:07-05:00Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) announced that the European Commission has granted Orphan Designation in the European Union for the Company's novel synthetic oral endocannabinoid-mimetic drug, Resunab, for the treatment of cystic fibrosis ("CF"). Read more >>

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis

Ziad2022-11-25T14:06:07-05:00Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed the Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic sclerosis ("systemic sclerosis"). Corbus expects to report topline data from this study in the fourth quarter of 2016. Read more >>

Hot Biotech Stocks To Watch Right Now: Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Ziad2022-11-25T14:06:07-05:00Corbus Pharmaceuticals Holdings, Inc. (CRBP) a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, announced that Professor Derek Gilroy, Ph.D. presented data on the effects of Resunab in a model of inflammation in healthy volunteers on September 28, 2016. The presentation was made at the 6th European Workshop on Lipid Mediators at Goethe University in Frankfurt am Main, Germany. Read more >>

Why Corbus Pharmaceuticals Holdings Inc Shares Skyrocketed Today

Ziad2022-11-25T14:06:07-05:00Corbus Pharmaceuticals (NASDAQ: CRBP) is up 29% at 1:18 p.m. EDT after an analyst at Cantor Fitzgerald initiated coverage of the biotech with a buy rating. There's plenty to learn about Corbus Pharmaceuticals. The biotech only has one drug, resunab, but it's testing the anti-inflammatory drug in multiple indications: cystic fibrosis, systemic sclerosis, dermatomyositis, and lupus. Read more >>